AGP Executive Report
Last update: 9 hours agoCancer Care in Europe: The EU CHMP has issued a positive opinion for Merck’s KEYTRUDA (pembrolizumab) plus PADCEV (enfortumab vedotin) as perioperative treatment for cisplatin-ineligible resectable muscle-invasive bladder cancer, with a final European Commission decision expected in Q3 2026—relevant for patients in Liechtenstein, Iceland and Norway. Rare Disease Treatment: Pharming won EU marketing authorization for Joenja (leniolisib) for activated PI3K delta syndrome (APDS), the first approved option in the EU for patients aged 12+; first launch is expected in Germany in Q3 2026, with coverage including Liechtenstein. Sexual Health Alert: New ECDC data shows STI diagnoses across Europe hit record highs, with England flagged as likely the worst-hit by volume for syphilis, chlamydia and gonorrhoea—an urgent reminder for prevention and testing. Privacy & Consumer Tech: A review of Incogni highlights automated data-broker removal claims (hundreds of brokers, millions of requests), plus an audit reference—useful for digital wellbeing. Travel Health/Rules: UK guidance warns travellers not to bring meat or dairy from the EU, with potential fines up to £5,000—important for safe travel.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.